Literature DB >> 6295272

Isolation of bromovinyldeoxyuridine-resistant strains of herpes simplex virus and successful chemotherapy of mice infected with one such strain by using acyclovir.

H J Field, J Neden.   

Abstract

Several strains of herpes simplex virus which were resistant to bromovinyldeoxyuridine were isolated by passaging the virus in the presence of the drug in tissue culture. The resistance of the majority of isolates was accounted for by their reduced ability to induce the enzyme thymidine kinase. These strains were co-resistant to acyclovir, but showed reduced pathogenicity in mice. However, another type of bromovinyldeoxyuridine-resistant virus was isolated which induced normal levels of thymidine kinase and retained virulence for mice. This resistant virus was sensitive to acyclovir and was successfully treated using oral acyclovir therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6295272     DOI: 10.1016/0166-3542(82)90048-1

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  11 in total

1.  Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.

Authors:  M N Ellis; P M Keller; J A Fyfe; J L Martin; J F Rooney; S E Straus; S N Lehrman; D W Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin.

Authors:  Graciela Andrei; Jan Balzarini; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Demonstration of viral thymidine kinase inhibitor and its effect on deoxynucleotide metabolism in cells infected with herpes simplex virus.

Authors:  L M Nutter; S P Grill; G E Dutschman; R A Sharma; M Bobek; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

4.  Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir.

Authors:  B A Larder; G Darby
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

5.  A precise termination site in the mouse beta-major globin transcription unit.

Authors:  M Salditt-Georgieff; J E Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates.

Authors:  J L Martin; M N Ellis; P M Keller; K K Biron; S N Lehrman; D W Barry; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

7.  DNA and RNA virus species are inhibited by xanthates, a class of antiviral compounds with unique properties.

Authors:  G Sauer; E Amtmann; K Melber; A Knapp; K Müller; K Hummel; A Scherm
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

8.  Cooperative effects between two acyclovir resistance loci in herpes simplex virus.

Authors:  G Darby; M J Churcher; B A Larder
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

Review 9.  Antiherpes drugs: promises and pitfalls.

Authors:  E de Clercq
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

Review 10.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.